ZKTECO CO.(SZ:301330) Sou Hu Cai Jing·2025-11-18 01:37Core Viewpoint - Entropy Technology (301330) is actively pursuing strategic acquisitions and expanding its brain-computer interface (BCI) technology, focusing on education, healthcare, and elderly care applications, while maintaining a strong cash flow and exploring further investment opportunities [2][3][4]. Group 1: Acquisition and Financial Performance - Entropy Technology signed a "Letter of Intent" with Longzhiyuan on October 17, 2025, to acquire a 55% stake, with completion expected by the end of November [2]. - For the first three quarters of 2025, the company reported a main revenue of 1.401 billion yuan, a year-on-year decrease of 0.68%, while net profit attributable to shareholders increased by 6.24% to 128 million yuan [7]. Group 2: Brain-Computer Interface Development - The company is focusing on BCI technology in three core application areas: education, healthcare, and elderly care, utilizing multi-modal data fusion technology for product development [3]. - A prototype for the BCI business is expected to be launched by March 2026, and a strategic partnership with NeuroSky has been established to enhance BCI and multi-modal biometric technology integration [3]. Group 3: Market Position and Strategy - The BCI business overlaps with existing clients in healthcare and education, while also targeting new customer segments in consumer electronics, industry, and research [5]. - The company emphasizes a dual strategy of organic growth and external development, with the acquisition of Longzhiyuan being its first since going public [4].